Company intelligence / Profile preview

Axovia Therapeutics

London, England, United Kingdomaxoviatherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Robust preclinical efficacy and toxicology data have been reported for the lead program AXV101, showing disease modification including rescue of vision loss by halting retinal degeneration in animal models. No human clinical results yet as trials are scheduled to begin mid/late 2025.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: Gene therapy using adeno-associated virus vectors (AAV9)
Industry: Biotech

Drug pipeline

3 assets

AXV-102

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

ALSA VenturesUniversity College LondonAlbionVCA Race Against Blindness grant funding ($1M)Academic collaboration roots at University College London via co-founders’ research.

Beyond the preview

Go deeper on Axovia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axovia Therapeutics.

Explore the full profile